Transcript · English → Indonesian
Discussion on COVID-19 Vaccine Development
Video ini dari enam Oktober 2021.
Aku mengadakan rapat dengan manajerku, Kanwal Gill, seorang
ilmuwan utama yang mengerjakan formulasi vaksin di Pfizer.
Dalam rapat ini, aku bertanya apakah boleh memberi orang-orang
suntikan eksperimental lagi terkait suntikan penguat atau
apakah itu demi mencari uang.
Jadi, apa kita—
Tapi kita masih—
Maksudku, apa kita tahu, kayak, maksudku, kalau dipikir-pikir,
secara etis, apa boleh, kayak, memberi orang-orang
suntikan eksperimental lagi? Kayak, apa kita yakin ini bakal aman dan
efektif, atau kita meluncurkannya hanya karena
kita ingin meluncurkannya
demi uang? Kayak—
Ya.
Ini data waktu nyata yang sedang kami hasilkan. Kami bahkan tidak tahu.
Saat kami mulai memvaksinasi orang, kami tak tahu akan seperti apa jadinya.
Ya.
Vaksin mRNA sudah ada selama 50 tahun, tapi tak ada yang masuk ke
tahap klinis. Kenapa? Karena vaksin mRNA diketahui
memiliki efek samping.
Benar. Tapi—
Moderna sudah— telah menelitinya selama sepuluh tahun.
Ini bukan hal baru, 'kan? Tapi alasan itu tak masuk uji klinis karena
semua efek samping ini. Kami, Pfizer dan Moderna, memanfaatkan
kedaruratan dan pandemi ini untuk meloloskannya sekarang.
Oke.
Tapi, kami tak… Bahkan untuk model CDC, kami tak punya data.
Jadi itu tak akan disetujui FDA hingga,
hingga terjadi kedaruratan ini, 'kan?
Maksudnya, kita harus mencoba hal baru, jadi.
Tapi kenapa kita tak mencoba, semacam, formulasi vaksin
yang efektif di masa lalu, seperti dengan kuning telur atau hal lain
yang ka— mereka pakai untuk flu, 'kan?
Eh, jadi—
Ya. Jadi kami di sini tidak melakukannya karena kami
sudah punya
kolaborasi dengan BioNTech untuk flu—
Mm-hm.
sebelum COVID benar-benar terjadi. Jadi mRNA…
Jadi apa yang ter— cerita di balik kami memulainya
karena orang BioNTech,
Üçüncü, sang CEO BioNTech, menelepon
Kathrin Jansen.
Üçüncü?
Ya. Dia menelepon Kathrin Jansen, dan dia bilang, "Hei, aku punya
teknologi ini, tetapi tidak punya sumber daya untuk membuatnya
besar."
Jadi Kathrin bilang, "Kami punya— kami sudah punya kerja sama
sebelumnya untuk flu," jadi kami, kami ingin mencobanya.
Ini hal mRNA baru. Tidak ada yang tahu apa pun tentangnya.
Kami tidak pernah memilikinya.
Kami tak pernah punya ini. Kami mu— Semuanya benar-benar
baru sejak tahun lalu.
Mencoba, belajar sambil berjalan.
Jadi kami punya… Kami sedang mu— Semuanya sambil berjalan.
Pandemi, luncurkan saja, luncurkan, luncurkan. Tak ada waktu untuk berpikir.
Itu saatnya bertindak.
Sosok yang disebut Kanwal di klip ini adalah Kathrin Jansen,
mantan kepala penelitian dan pengembangan vaksin di Pfizer.
Saya Kathrin Jansen. Saya mengembangkan vaksin
yang membantu jutaan orang
di seluruh dunia terlindung dari infeksi ganas dan mematikan.
Saat ini, saya mengembangkan kandidat vaksin untuk membantu
mencegah
COVID-19.
End of transcript · 424 words · machine translated
Original transcript (English)
This video here is from October sixth, twenty twenty-one. I had a meeting with my manager, Kanwal Gill, a principal scientist working on the vaccine formulation at Pfizer. In this meeting, I asked her if it was okay to give people another experimental injection regarding the booster shots or
if it was a drive for money. So are we- But we are still- Like, do we know that, like, I mean, just thinking, like, ethically, like, is it okay to, like, give people another
experimental injection? Like, are, are we sure it's gonna be safe and effective, or are we just rolling these out because we wanna roll them out for money? Like- Yeah.
This is a real-time data that we are generating. We don't even know. When we started vaccinating people, we had no idea how it's gonna look like. Yeah. mRNA vaccines have been there for fifty years, you know, but nothing went to clinical. Why? Because mRNA vaccines have been known to
have side effects. Right. But- Moderna was-- has been working on it for ten years. This is not the new thing, right? But why it did not reach trial was because of all these side effects. We, Pfizer and Moderna, used the
emergency and the pandemic to kind of get through it now. Okay. But, you know, we didn't... But even CDC model, we don't have data. So it could never get FDA approved until, until we had this emergency, right?
Like, we had to try something new, so. But why didn't we try, like, a vaccine formulation that has been effective in the past, like with egg yolk or something that you-- they use with flu, right? Uh, so-
Yeah. So we here did not do it because we already have collaboration with BioNTech on flu- Mm-hmm ... before actually COVID happened. So mRNA...
So what hap-- what a story behind we starting on this because BioNTech guy, Üçüncü, the BioNTech CEO, he called Kathrin Jansen. Üçüncü?
Yeah. He called Kathrin Jansen, and he's like, "Hey, I have this technology, but I don't have resources to make it big." So Kathrin was like, "Well, we have-- we had a collaboration in place before for flu," so we, we wanted to give it a shot.
It is a new mRNA thing. Nobody knew anything about it. We never had it. We never had this. We are sta-- Everything is just fresh from last year. Trying, learning on the fly.
So we had... We were starting-- It was on a fly. Pandemic, just roll it out, roll it out, roll it out. There was no time to think. It was a time to act. Who Kanwal was mentioning in this clip is Kathrin Jansen, the former head of vaccine research and development at Pfizer.
I'm Kathrin Jansen. I develop vaccines which help millions of people around the world to be protected from nasty and deadly infections. Currently, I'm developing a vaccine candidate to help prevent
COVID-19.
